Why the study?
Whether and how protein kinase A (PKA) plays a role in physiological and pathological cardiac hypertrophy was not clear.
Does cPKAi ameliorate pathological cardiac hypertrophy in preclinical models?
Does cPKAi ameliorate pathological cardiac hypertrophy in preclinical models?
Cardiomyocyte PKA inhibition represents a potential novel therapeutic approach to treat pathological cardiac hypertrophy by regulating protein synthesis and degradation.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice; hypothesis-generating for PKA inhibition in human hypertrophy.
Bai et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: